

Amendments to the Specification:

Please replace the previously amended paragraph [0214] with the following amended paragraph:

[0214] Specifically, as shown in cross-sectional views Figs. 45, 46 and 47, the valve assembly 750 includes a plastic button 751 slidably engaged within a rubber stopper 752 in fluid communication with the reservoir 710. That is, for fluid communication ~~the reservoir 710 and valve assembly 750 have a reservoir port 716 where~~ the released contents of the reservoir first leave the containment of the reservoir, and ~~have a needle port 718 where the released contents~~ are directed to then travel to the needle. The valve assembly 750 has as an initial state and an activated state, and includes a large diameter distal end having a distal set of radially projecting fins, or ribs 753 forming a body seal, and a reduced diameter proximal end having a proximal set of detents 754 forming a reservoir seal ~~at the reservoir port 716~~. As shown in Fig. 47, the reservoir seal of detents 754 is within the fluid flow path ~~between ports 716 and 718~~, whereas only one side, the inner side, of the body seal is ever in contact with the fluid flow path ~~between ports 716 and 718~~. The outer side of the body seal of ribs 753 facing the button 751 are never in contact with the fluid flow path ~~between ports 716 and 718~~. In use, the button 751 will eventually be pushed into an activated state by the movement of the push button 780 and the set of detents 754 will be advanced from engagement with the rubber stopper 752, which permits the drug to flow from the reservoir 710, past the detents 754 and into the fluid path 713. As stated above, a significant benefit to each embodiment described above includes the ability to achieve each step in a single push button action. Additionally, another significant benefit includes the use of a continuous fluid communication path comprised of the reservoir subassembly.